RT Journal Article
SR Electronic
T1 Pharmacoeconomics: <em>Growth in Cancer Diagnostics Means Market Opportunity</em>
JF The Journal of Private Equity
FD Institutional Investor Journals
SP 48
OP 50
DO 10.3905/jpe.2017.21.1.048
VO 21
IS 1
A1 Paul Crowe
YR 2017
UL https://pm-research.com/content/21/1/48.abstract
AB Testing for precision diagnostics in cancer is underway in Food and Drug Administration clinical trials. This new technology will outdate current, inaccurate technologies (i.e., mammograms and prostate-specific antigen tests) and become part of routine health screenings. Cost savings translate to bigger profit potential for hospitals and laboratories that conduct the tests. Trends in precision medicine will turn the diagnostics sector from its current moderate value/moderate growth status to one replicating the explosive growth of biotech.TOPICS: Private equity, legal/regulatory/public policy, portfolio construction, other real assets